Anti-herpes virus activities of bioactive fraction and isolated pure constituent of Mallotus peltatus: an ethnomedicine from Andaman Islands

Virology Journal

Sekhar Chakraborti²  Gobardhan Das¹  Tapan Chatterjee³  Mamta Chawla Sarkar²  Nilanjan Mandal⁴  Durbadal Ojha⁴  Hemanta Mukherjee⁴  Debprasad Chattopadhyay⁴  Paromita Bag⁴ 

[1] Immunology Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India;Division of Virology, National Institute of Cholera & Enteric Diseases, Kolkata, India;Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India;ICMR Virus Unit, ID & BG Hospital, General Block 4, First floor, 57 Dr Suresh Chandra Banerjee Road, Beliaghata, Kolkata, 700010, India

关键词: Ursolic acid;    Herpes simplex virus;    Antiviral activity;    Ethnomedicine;    Mallotus peltatus;   

Others  :  1154642
DOI  :  10.1186/1743-422X-9-98

 received in 2011-11-01, accepted in 2012-05-24,  发布年份 2012

【 摘 要 】

Background

Viral infections, particularly the infections caused by herpes simplex virus (HSV), represent one of the most serious public health concerns globally because of their devastating impact. The aim of this study was to evaluate the antiviral potential of methanolic crude extract of an ethnomedicine Mallotus peltatus, its active fraction and pure compound, against HSV-1 F and HSV-2 G.

Result

The cytotoxicity (CC₅₀, the concentration of 50% cellular toxicity), antiviral effective concentration (EC₅₀, the concentration required to achieve 50% protection against virus-induced cytopathic effect), plaque reduction and the selectivity index (SI, the ratio of CC₅₀ and EC₅₀) was determined. Results showed that the crude methanolic extract of M. peltatus possessed weak anti-HSV activity. In contrast, the active fraction A and isolated ursolic acid from fraction A exhibited potent antiherpesvirus activity against both HSV-1 (EC₅₀ = 7.8 and 5.5 μg/ml; SI = 22.3 and 20) and HSV-2 (EC₅₀ = 8.2 and 5.8 μg/ml, and SI = 21.2 and 18.97). The fraction A and isolated ursolic acid (10 μg/ml) inhibited plaque formation of HSV-1 and HSV-2 at more than 80% levels, with a dose dependent antiviral activity, compared to acyclovir. The time response study revealed that the anti-HSV activity of fraction A and isolated ursolic acid is highest at 2–5 h post-infection. Moreover, the time kinetics study by indirect immunofluorescence assay showed a characteristic pattern of small foci of single fluorescent cells in fraction A- treated virus infected cells at 2 h and 4 h post-infection, suggesting drug inhibited viral dissemination. Further, the PCR study with infected cell cultures treated with fraction A and isolated ursolic acid at various time intervals, failed to show amplification at 48–72 h, like acyclovir treated HSV-infected cells. Moreover, fraction A or isolated ursolic acid showed no interaction in combination with acyclovir.

Conclusion

This study revealed that bioactive fraction A and isolated ursolic acid of M. peltatus has good anti-HSV activity, probably by inhibiting the early stage of multiplication (post-infection of 0–5 h), with SI value of 20, suggesting its potential use as anti-HSV agents.

【 授权许可】

   
2012 Bag et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Barton S: The role of anti-HSV therapeutics in the HIV-infected host and in controlling the HIV epidemic. Herpes 2005, 12:15-22.
• [2]Fatahzadeh M, Schwartz RA: Human herpes simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis, and management. J Am Acad Dermatol 2007, 57(5):737-763.
• [3]Cowan FM, French RS, Mayaud P, Gopal R, Robinson NJ, de Oliveira SA, Faillace T, Uusküla A, Nygård-Kibur M, Ramalingam S, Sridharan G, El Aouad R, Alami K, Rbai M, Sunil-Chandra NP, Brown DW: Seroepidemiological study of herpes simplex virus types 1 and 2 in Brazil, Estonia, India, Morocco, and Sri Lanka. Sex Transm Infect 2003, 79(4):286-290.
• [4]Safrin S, Crumpacker C, Chatis P, Davis R, Hafner R, Rush J, Kessler HA, Landry B, Mills J: A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med 1991, 325(8):551-555.
• [5]White MK, Gorrill TS, Khalili K: Reciprocal transactivation between HIV-1 and other human viruses. Virology 2006, 352:1-13.
• [6]Wald A: Synergistic interactions between herpes simplex virus type-2 and human immunodeficiency virus epidemics. Herpes 2004, 11:70-76.
• [7]Mbopi-Kéou FX, Grésenguet G, Mayaud P, Weiss HA, Gopal R, Matta M, Paul JL, Brown DW, Hayes RJ, Mabey DC, Bélec L: Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: opportunities for intervention. J Infect Dis 2000, 182(4):1090-1096.
• [8]Nagot N, Ouédraogo A, Foulongne V, Konaté I, Weiss HA, Vergne L, Defer M-C, Djagbaré SA, Andonaba J-B, Becquart P, Segondy M, Vallo R, Sawadogo A, Van de Perre P, Mayaud P: Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 2007, 356:790-799.
• [9]Morfin F, Thouvenot D: Herpes simplex virus resistance to antiviral drugs. J Clin Virol 2003, 26(1):29-37.
• [10]Reyes M, Shaik NS, Graber JM, Nisenbaum R, Wetherall NT, Fukuda K, Reeves WC: Task Force on Herpes Simplex Virus Resistance, Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch Intern Med 2003, 163(1):76-80.
• [11]Miserocchi E, Modorati G, Galli L, Rama P: Efficacy of valacyclovir vs acyclovir for the prevention of recurrent herpes simplex virus eye disease: a pilot study. Am J Ophthalmol 2007, 144(4):547-551.
• [12]Narayana K: A purine nucleoside analogue-acyclovir [9-(2-hydroxyethoxymethyl)-9 h-guanine] reversibly impairs testicular functions in mouse. J Toxicol Sci 2008, 33(1):61-70.
• [13]Brigden D, Rosling AE, Woods NC: Renal function after acyclovir intravenous injection. Am J Med 1982, 73(1A):182-185.
• [14]Sawyer MH, Webb DE, Balow JE, Straus SE: Acyclovir-induced renal failure Clinical course and histology. American J Med 1988, 84(6):1067-1071.
• [15]Stanberry LR: Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. Herpes 2004, 11(A):161-169.
• [16]Koelle DM: Vaccines for herpes simplex virus infections. Curr Opin Investig Drugs 2006, 7:136-141.
• [17]Chattopadhyay D, Khan MTH: Ethnomedicines and ethnomedicinal phytophores against Herpesviruses. Biotechnol Annu Rev 2008, 14:297-348.
• [18]Bhargava N: Ethnobotanical studies of the tribes of Andaman and Nicobar Islands India I Onge. Econ Bot 1983, 37:110-119.
• [19]Dagar HS, Dagar JC: Plant folk medicines among Nicobarese of Katchal Island, India. Econ Bot 1991, 45:114-119.
• [20]Chattopadhyay D, Arunachalam G, Mandal AB, Sur TK, Mandal SC, Bhattacharya SK: Antimicrobial and anti-inflammatory activity of Mallotus peltatus leaf extract. J Ethnopharmacol 2002, 82:229-237.
• [21]Chattopadhyay D, Arunachalam G, Sur TK, Bhattacharya SK, Mandal AB: Analgesic and Antiinflammatory Activity of Alstonia macrophylla and Mallotus peltatus leaf extracts: two popular ethnomedicines of Onge, a Negrito tribe of little Andaman. Oriental Pharm Exp Med 2005, 5(2):124-136.
• [22]Chattopadhyay D, Arunachalam G, Mandal AB, Bhattacharya SK: Pharmacological activities of three Ethnomedicines of Little Andaman. In Recent progress in Medicinal Plants, Search for natural Drugs. Edited by Govil JN, Singh VK, Arunachalam C. Studium Press LLC, Houston; 2006:511-537.
• [23]Chattopadhyay D, Maiti K, Kundu AP, Chakrabarty MS, Bhadra R, Mandal SC, Mandal AB: Antimicrobial activity of Alstonia macrophylla: folklore of Bay Islands. J Ethnopharmacol 2001, 77:49-55.
• [24]Pollock JRA, Stevens R: Dictionary of Organic Compounds, Volume 5. 4th edition. Eyre and Spottiswoode, London; 1965.
• [25]Mindel A: Genital herpes-how much of a public-health problem? Lancet 1988, 351:16-18.
• [26]Hsiang CY, Hsieh CL, Wu SL, Lai IL, Ho TY: Inhibitory effect of anti-pyretic and anti-inflammatory herbs on herpes simplex virus replication. Am J Chin Med 2001, 29(3–4):459-467.
• [27]Wilson Anne P: Cytotoxicity and viability. In Animal Cell Culture: A Practical Approach. 3rd edition. Edited by Masters John RW. Oxford University Press, Oxford; 2000. Chapter 7. ISBN 978–0199637966
• [28]Zhang Y, But P-H, Ooi E-CV, Xu H-Xi, Delaney GD, Lee Spencer HS, d Lee SF: Chemical properties, mode of action, and in vivo anti-herpes activities of a lignin-carbohydrate complex from Prunella vulgaris. Antiviral Research 2007, 75(3):242-249.
• [29]Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65(1–2):55-63.
• [30]Chattopadhyay D, Chawla Sarkar M, Chatterjee T, Dey R, Bag P, Chakrabarty S, Khan MTH: Recent advancements for the evaluation of Antiviral activities of natural products. New Biotechnology 2009, 25(5):347-368.
• [31]Chiang LC, Chiang W, Liu MC, Lin CC: In vitro antiviral activities of Caesapinia pulcherrima and its related flavonoids. J Antimicrob Chemother 2003, 52:194-198.
• [32]Villamil SM, Alche LE, Coto CE: Inhibition of herpes simplex virus type-1 multiplication by meliacine a peptide of plant origin. Antivir Chem Chemother 1995, 6:239-244.
• [33]Verma H, Patil PR, Kolhapure RM, Gopalkrishna V: Antiviral activity of the Indian medicinal plant extract, Swertia chirata against herpes simplex viruses: a study by in vitro and molecular approach. Indian J Med Microbiol 2008, 26(4):322-326.
• [34]Suhnel J: Evaluation of synergism or antagonism for the combined action of antiviral agents. Antiviral Res 1990, 13:23-39.
• [35]Lawetz C, Liuzzi M: The antiviral activity of the ribonucleotide reductase inhibitor BILD 1351 Se in combination with acyclovir against HSV type-1 in cell culture. Antiviral Res 1998, 39:35-46.
• [36]Piret J, Roy S, Gagnon M: Comparative study of mechanism of herpes simplex virus in activation by sodium lauryl sulphate and n-lauroylsarcosine. Antimicrob Agents Chemother 2002, 46:2933-2942.
• [37]Cheng HY, Lin TC, Yang CM, Wang KC, Lin LT, Lin CC: Putranjivain A from Euphorbia jolkini inhibits both virus entry and late stage of replication of herpes simplex virus type 2 in vitro. J Antimicrob Chemother 2004, 53:577-583.
• [38]Chattopadhyay D, Arunachalam G, Mandal AB, Mandal SC: Evaluation of Antipyretic activity of leaf extracts of Mallotus peltatus (Geist) Muell. Arg.: A folk medicine. Phytomedicine 2002, 9:632-635.
• [39]Kleymann G: New antiviral drugs that target herpesvirus helicase primase enzymes. Herpes 2003, 10(2):46-52.
• [40]Sweetman S: The complete drug reference. 34th ed. Edited by Martindale . Pharmaceutical Press, London; 2004:550-554. ISBN 0–85369
• [41]Rastogi RP: Mallotus. In Compendium of Indian Medicinal Plants. Publications & Informations Directorate, CSIR, New Delhi; 1992:450.
• [42]Sastri BN: Wealth of India, Raw Materials; Vol. 1A, 199–200. Publications & Information Directorate, CSIR, New Delhi; 1985:1948-1976.
• [43]Yamagishi T, Zhang DC, Chang JJ: The cytotoxic principle of Hyptis capitata and structure of new triterpene hyptatica acid A and B. Phytochemistry 1988, 27(321):3-6.
• [44]Kim KW: Anticancer Activities of Plant Triterpenoids, Ursolic acid and Oleanoid acid. J Korean Assoc Cancer Prev 1997, 2:38-44.
• [45]Kim SH, Song GY, Ryu SY: Antitumor and antimetastatic activities of ursolic acid. Korean J Oriental Med Pathol 1999, 13:65-75.
• [46]Simon A, Delage C, Saux M, Chulia A, Najida A, Rigaud M: Structure of ursolic acid ethanol solvate. Acta Crystallogr C 1992, 48:726-728.
• [47]Muto Y, Ninomiya M, Fujiki H: Present status on cancer chemoprevention in Japan. Jpn J Clin Oncol 1990, 20:219-224.
• [48]Kashiwada Y, Wang HK, Nagao T: Anti-AIDS Agents. 30 anti-HIV activity of oleanolic acid. Promolic acid and structurally related triterpenoids. J Natural Product 1998, 61:1090-1095.
• [49]Kowalewski Z, Kortus M, Edzia W, Koniar H: Antibiotic action of ursolic acid. Arch Immunol et Ther Exp (Warsz) 1976, 24:115-119.
• [50]Arunachalam G, Chattopadhyay D, Mandal AB, Sur TK, Mandal SC: Evaluation of antiinflammatory activity of Alstonia macrophylla wall ex A.DC. Leaf extract. Phytomedicine 2002, 9:727-730.
• [51]Najid A, Simon A, Cook J, Chable-Rabinobitch H, Delage C, Chulia A, Riguad M: Characterization of ursolic acid as a lipoxygenase and cyclooxygenase inhibitor using macrophages, platelets and differentiated HL60 leukemic cells. FEBS Lett 1992, 229:213-217.
• [52]Ringbom T, Segura L, Noreem Y, Perera P, Bohlin L: Ursolic acid from Plantago major, a selective inhibition of cyclooxygenase-2 catalyzed prostaglandin biosynthesis. J Nat Prod 1998, 61:1212-1215.
• [53]Wang BH, Polya GM: Selective inhibition of cyclic AMP-Dependent protein kinase by amphiliphilic triterpenoids and related compounds. Phytochemistry 1996, 41:55-63.
• [54]Mizushina Y, Iida A, Ohta K, Sugawara F, Sakaguchi K: Novel triterpenoids inhibit both DNA polymerase and DNA topoisomerase. Biochem J 2000, 350:757-763.
• [55]Kim JS, Huh JI, Song SH: The antioxidative mechanism of ursolic acid. Korean J Gerontol 1996, 6:52-56.
• [56]Kim DK, Baek JH, Kang CM: Apoptotic activity of ursolic acid may correlate with the inhibition of DNA replication. Int J Cancer 2000, 87:629-636.
• [57]Choi YH, Baek JH, Yoo MA, Chung HY, Kim ND, Kim KW: Induction of apoptosis by ursolic acid through activation of caspases and down-regulation of c-IAPs in human prostate epithelial cells. Int J Oncol 2000, 17:565-571.
• [58]Abe F, Yamauchi T, Nagao T, Kinjo J, Okabe H, Higo H, Akahane H: Ursolic acid as a trypanocidal constituent in rosemary. Biol Pharm Bull 2002, 25:1485-1487.
• [59]Yucharoen R, Anuchapreeda S, Tragoolpua Y: Anti-herpes simplex virus activity of extracts from the culinary herbs Ocimum sanctum L., Ocimum basilicum L. and Ocimum americanum L. Afr J Biotechnol 2011, 10(5):860-866.
• [60]Katsuo M, Hiroki T, Norio F, Yasutomo N, Yukiko Y: Photoaging inhibitor and dermal agent for external use. , ; 1997. Japanese Patent No. 09143050